2013 Statement on Human Papillomavirus DNA Test Utilization
| Autor: | Diane Davis, Davey, Robert, Goulart, Ritu, Nayar, Mark, Stoler |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Statement (logic) MEDLINE Uterine Cervical Neoplasms Cervical cancer screening Pathology and Forensic Medicine Internal medicine Health care medicine Humans Mass Screening DNA Probes HPV Education and technology Human Papillomavirus DNA Test Mass screening Cervical pathology Colposcopy Gynecology medicine.diagnostic_test Clinical pathology business.industry Papillomavirus Infections Cancer General Medicine Middle Aged medicine.disease Cytopathology Family medicine Practice Guidelines as Topic Female business Papanicolaou Test |
| Zdroj: | Journal of the American Society of Cytopathology. 3(2) |
| ISSN: | 2213-2945 |
| Popis: | In 2009, the Cytopathology Education and Technology Consortium issued a statement on human papillomavirus (HPV) DNA test utilization that was published in multiple journals.1 This statement was a concise summary of the clinical indications for high-risk or oncogenic HPV testing based on guidelines from the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS) published from 2002 through 2007.2,3 These organizations have since published newer consensus guidelines addressing HPV testing,4,5 and the previous summary no longer reflects current screening and management guidelines. High-risk HPV testing has proven utility in both cervical cancer screening and management. The 2012 screening guidelines endorsed by the ACS, ASCCP, and the American Society for Clinical Pathology state that combined cervical cytology and HPV testing is now the preferred strategy for women 30 years and older. The 2012 ASCCP guidelines for the management of abnormal cervical cancer screening tests and cancer precursors utilize cotesting extensively as both a sensitive and efficient way to manage and follow these women. Inappropriate or too-frequent screening, including HPV testing, can lead to increased costs without proven benefit and may also cause patient harm by overtreatment. The educational statement below is intended to improve adherence to current guidelines, thereby improving the health care of women. The American College of Obstetricians and Gynecologists affirms these recommendations and … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect